Authors' objectives: AA amyloidosis is a rare and serious condition that can happen as a complication of other chronic diseases such as rheumatoid arthritis. It leads to abnormal proteins being deposited throughout the body, but particularly affects the kidneys. Many patients eventually have kidney failure and need to start dialysis. At the moment, there is no treatment for AA amyloidosis itself, only the chronic disease that is causing it. Eprodisate disodium (Kiacta) is a new drug being developed for AA amyloidosis. It is taken as a tablet twice a day. A study is currently running to see how well it works and whether it is safe to use. If it is licensed in the UK, eprodisate disodium will be the first treatment specifically available for people with AA amyloidosis.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/eprodisate-disodium-kiacta-for-aa-amyloidosis/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)